26 Chapter 2 Table 1. Key characteristics of the three national cancer screening programmes in the Netherlands Cervical CSP Breast CSP Colorectal CSP Since (year) 1979 (pilots from 1976) 1990 (pilots from 1984) 2014 (will be fully operational in 2019) Population Age category 30-60 50-75 55-75 Sex F F F&M Interval (in years) 5 2 2 Primary test hrHPV-test, cytology if necessary (then a Pap-smear as needed) Mammography (bilateral) FIT Involvement GP Performing cytological smear, discuss outcome, hospital referrala Discuss outcome, hospital referralb Nonec Primary outcome KOPAC-coded BI-RADS-code Negative, positive, unclear. Financing Invitation, primary test and analyses, referral when abnormalities are detected Dutch government Secondary tests & potential treatment Standard healthcare, thereafter, depending on individual insurance policy F= Female, M= Male, hrHPV= high-risk Human papillomavirus, FIT= Faecal Immunochemical Test, GP= General Practitioner aFrom 2017 onward, women can choose a self-sampling test. The outcome (negative, positive, or unclear) of the self-sampling test is not automatically shared with the GP, so the GP no longer plays an essential role in this CSP. If hrHVP is detected, women are advised to seek contact with their GP to perform a Pap smear at the GP’s office. bIn cases where no abnormalities are detected the GP will not be involved. cSince 2017 the GP no longer automatically receives the outcome of a FIT. However, after a positive FIT patients are encouraged to seek contact with their GP. dKOPAC-code is a Dutch classification system comparable with the Pap-classification.
RkJQdWJsaXNoZXIy MTk4NDMw